Chitosan nano-selenium particles, preparation method thereof and application of chitosan nano-selenium particles in vaccines

A chitosan nano and chitosan technology, applied in the field of vaccine development, can solve the problems of inability to convert functional immunogens, premature molecular degradation, and low risk of infection, so as to improve humoral immunity and cellular immune response, and improve richness and the effect of good antigen loading capacity

Pending Publication Date: 2021-06-01
JIANGNAN UNIV
View PDF6 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

RNA or DNA vaccines have minimal risk of infection, can elicit an immune response against a specific pathogen, and are inexpensive; but face the problem of premature degradation of the molecule and inability to convert into a functional immunogen

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chitosan nano-selenium particles, preparation method thereof and application of chitosan nano-selenium particles in vaccines
  • Chitosan nano-selenium particles, preparation method thereof and application of chitosan nano-selenium particles in vaccines
  • Chitosan nano-selenium particles, preparation method thereof and application of chitosan nano-selenium particles in vaccines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1～11

[0035] The preparation of chitosan nano-selenium of the present invention is by changing sodium selenite (Na 2 SeO 3 ), ascorbic acid (Vc), the ratio of chitosan, and conditions such as temperature of reaction, reaction time make the chitosan nano-selenium of different particle diameters, and concrete preparation method is as follows:

[0036] According to the ratio and reaction conditions shown in Tables 1-3, take 2.50 mL of acetic acid solution of chitosan in a 10 mL centrifuge tube, add 40.00 μL of sodium selenite solution and magnetically stir at room temperature for 6 hours, add 200.00 μL of ascorbic acid solution, Add acetic acid solution to make the final volume 5.00mL, mix well and let stand in the dark for 12h at room temperature or under heating conditions. Finally, the chitosan nano-selenium solution that has been reacted is installed in a dialysis bag with a molecular weight cut-off of 10000kD, dialyzed in deionized water at room temperature for 24 hours, and chan...

Embodiment 12～13

[0047] Compared with Example 1 and Example 13, the difference between Example 12 and Example 3 is that the reaction system is increased from 5mL to 250mL, and the rest of the reaction conditions are unchanged, so that Example 12 and Example 3 are obtained. 13 chitosan nano-selenium particles.

[0048] Such as figure 1 Shown is the transmission electron micrograph of the chitosan nano selenium particle of embodiment 12, from figure 1 It can be seen that the chitosan nano-selenium particles in Example 12 are spherical, with a solid core inside, and the particle diameter is less than 100 nm, about 80 nm.

[0049] The comparison of the measured Size, PdI, and Zeta values ​​of the chitosan nano-selenium particles of Example 12 and Example 13 with the reaction volume of 5 mL is shown in Table 4 below.

[0050] Table 4 reaction system volume is the prepared chitosan nano selenium of 5mL and 250mL

[0051]

[0052] As can be seen from Table 4, the volume of the reaction system h...

Embodiment 14

[0068] Because the chitosan nano-selenium particle quality that embodiment 12 and 13 make is the highest, particle uniformity is better, and Zeta potential is higher, therefore, the chitosan nano-selenium particle that makes with embodiment 12 and 13 is sample (respectively Labeled as CS-SeNP-12, CS-SeNP-13) for the preparation and characterization of vaccine samples, mouse immunization experiments.

[0069] 1. Preparation and characterization of vaccine samples

[0070] The first group of vaccine preparation: OVA+chitosan+aluminum adjuvant (vaccine 1), take by weighing 2.8mg chitosan and be dissolved in 0.01mol / L2mL dilute acetic acid solution and then the sodium hydroxide solution of equal concentration and equal volume is neutralized, then use Adjust the pH to 7.4 with high-concentration 1M hydrochloric acid, add OVA, and add aluminum adjuvant at a ratio of 1:1, and mix well.

[0071] Preparation of the second group of vaccines: CS-SeNP-12 (vaccine 2), according to the con...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
concentrationaaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses chitosan nano-selenium particles, a preparation method thereof and application of the chitosan nano-selenium particles in vaccines, and the chitosan nano-selenium particles are prepared from chitosan, sodium selenite and other raw materials and can achieve efficient wrapping of antigens and vaccine adjuvants. The chitosan nano-selenium particles disclosed by the invention have extremely good biological safety. The chitosan nano-selenium particles have good physical stability and thermal stability, and are suitable for industrial preparation of vaccines. As an immune carrier or adjuvant, the chitosan nano-selenium particles can promote phagocytosis, treatment and presentation of antigen-presenting cells to antigens, induce generation of higher-level antigen-specific IgG antibody titer, and have important application value in the field of vaccine development.

Description

technical field [0001] The invention relates to the technical field of vaccine development, and more specifically relates to a chitosan nano-selenium particle, a preparation method thereof and an application in vaccines. Background technique [0002] The development of vaccines has undergone several generations of technology updates. Live attenuated vaccines and inactivated vaccines are widely used to prevent severe viral diseases including yellow fever, measles and polio, but they have the disadvantages of difficult cultivation, easy infection, and easy to cause excessive immune response. Subunit vaccines, including proteins, polysaccharides or other pathogenic components, such as influenza type b, diphtheria, tetanus, acellular perforation disease, meningococcus and pneumococcus, etc., but they also require adjuvants to enhance their immunogenicity, and Early degradation often occurs after exposure to a hostile in vivo environment. Ribonucleic acid or deoxyribonucleic ac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/385A61K39/39A61K47/61A61K47/52A61K47/69A61K39/00A61P35/00
CPCA61K39/385A61K39/39A61K47/61A61K47/52A61K47/6939A61K39/0011A61P35/00A61K2039/55583A61K2039/55505A61K2039/6087A61K2039/60A61K2039/575
Inventor 周志昉俞杭艳汪楚卉解云天林汉
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap